Close this search box.

Caffeine and Parkinson’s disease: Understanding the connection

dyskinesia Parkinson's disease

For years, the potential health benefits of caffeine have been a topic of interest, particularly its impact on neurodegenerative diseases like Parkinson’s. While past epidemiological studies have suggested that caffeine may offer protective benefits against the development of Parkinson’s disease, recent research delves into whether it can also aid in treating the condition.

The protective role of caffeine

Research indicates that individuals who consume higher levels of caffeine are less likely to develop Parkinson’s compared to non-consumers. The protective mechanism of caffeine may involve its role as an adenosine receptor antagonist, which could indirectly increase dopamine release and potentially guard against Parkinson’s disease.

Does caffeine improve Parkinson’s symptoms?

However, when it comes to treating Parkinson’s, the evidence is less clear. A study published in the Annals of Neurology concludes that caffeine does not improve symptoms for those already diagnosed with the disease. This finding challenges the notion that caffeine could be a therapeutic agent for Parkinson’s symptom management.

Caffeine’s impact on brain scans

An intriguing aspect of the study is the discovery that caffeine consumption before a brain scan can influence the results. This could have implications for clinical practice, suggesting that patients might need to avoid caffeine before undergoing certain diagnostic tests to ensure accurate results.

Understanding dopamine function

The recent study investigated caffeine’s effect on dopamine function in individuals with Parkinson’s. Surprisingly, high caffeine intake was associated with reduced dopaminergic activity, contrary to expectations. Despite this reduction, there was no measurable worsening of symptoms in the high-caffeine group.

Implications for clinical practice

The research also indicates that caffeine intake before a dopamine transporter binding scan could affect the scan’s results. This raises the question of whether clinical guidelines should be updated to recommend caffeine avoidance before such imaging procedures.


While caffeine may lower the risk of developing Parkinson’s, it does not appear to alleviate symptoms or slow progression in those with the disease. The relationship between caffeine consumption and diagnostic imaging is an area that requires further investigation. As the scientific community continues to explore this connection, it remains a significant point of interest for both researchers and those affected by Parkinson’s disease.